Pipeline

Avacta will be in the clinic with its lead pre|CISIONTM targeted chemotherapy programme in mid-2020 and has a pre-clinical pipeline of Affimer® immunotherapy candidates. 

Avacta’s long term focus is on achieving a more durable response for patients through synergy of the innate immune response to pre|CISIONTM chemotherapies with the adaptive immune response to Affimer® immunotherapies in the form of co-administered combinations and in novel tumour-microenvironment activated drug conjugates (TMAC®).

Its lead Affimer® programme is a PD-L1 antagonist which will form the basis of future bispecifics and TMAC drug conjugates. The lead pre|CISIONTM programme is a tumour targeted form of Doxorubicin.

Beyond these two main programmes, the company is exploring a number of I-O antagonists and agonists, and other pre|CISIONTM pro-drugs, to support future programmes and partnering.

Click on the red bars in the pipeline infographic below for more information.

Programme
Lead optimisation
Pre-clinical
Phase 1
Partner
pre|CISIONTM AVA6000 | FAP-Activated Doxorubicin Prodrug
AVA004 | PD-L1 Checkpoint Inhibitor
AVA021 | PD-L1 Affimer® / LAG-3 Affimer Bispecific Checkpoint Inhibitor
AVA027 | PD-L1 Affimer® / TGFβ Trap Bispecific
TMAC® AVA004/100 | PD-L1 Affimer® / I-DASH Inhibitor
Oncology – Undisclosed Checkpoint Inhibitor
Oncology – Undisclosed Checkpoint InhibitorLead Optimisation
logo
Vascularization Disorders – Undisclosed Target
Vascularization Disorders – Undisclosed TargetLead Optimisation
logo
Affimer-Drug Conjugate – Undisclosed Oncology Target
Affimer-Drug Conjugate – Undisclosed Oncology TargetLead Optimisation
ADCTx logo

Discovery Pipeline

Programme
Targets
Checkpoints
PD-L1
PD-1
LAG-3
Costimulatory Pathways
4-1BB
CD40
CD27
CD28
GITR
Tumour Targeting
FAPa
Mesothelin
PK/ADME Modifiers
Human Serum Albumin
Hyaluronic Acid
FcRn
Transferrin Receptor